Close Menu

NEW YORK – Immuno-oncology imaging firm ImaginAb has initiated a Phase II trial of its positron emission tomography (PET) imaging agent [89] Zr-Df-IAB22M2C at Dana-Farber Cancer Institute.

The imaging agent uses antibody fragments, so called "minibodies," engineered by ImaginAb to target CD8-positive T cells, and illuminate them with the help of PET imaging. The platform is being developed to provide a whole-body snapshot of immune activity, including that of cancer lesions, which in turn could be used to tailor treatment more precisely to patients.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.